Microscopic polyangiitis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:727M31.7
Who is this for?
Show terms as
1FDA treatments41Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Microscopic polyangiitis (MPA) is a rare systemic autoimmune disease classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It is characterized by necrotizing inflammation of small blood vessels (capillaries, venules, and arterioles) without granulomatous formation, distinguishing it from granulomatosis with polyangiitis (formerly Wegener's). MPA primarily affects the kidneys and lungs, though it can involve virtually any organ system including the skin, peripheral nerves, gastrointestinal tract, and musculoskeletal system. Most patients are positive for perinuclear ANCA (p-ANCA) directed against myeloperoxidase (MPO-ANCA). The hallmark renal manifestation is rapidly progressive glomerulonephritis (pauci-immune necrotizing and crescentic glomerulonephritis), which can lead to kidney failure if untreated. Pulmonary involvement frequently presents as alveolar hemorrhage, which can be life-threatening. Other common symptoms include constitutional features such as fever, weight loss, fatigue, and myalgias. Skin manifestations may include purpura, livedo reticularis, and skin ulcers. Peripheral neuropathy, particularly mononeuritis multiplex, occurs in a significant proportion of patients. Treatment of MPA typically involves two phases: induction of remission and maintenance therapy. Induction therapy generally consists of high-dose glucocorticoids combined with either cyclophosphamide or rituximab. Plasma exchange may be considered in patients with severe renal disease or pulmonary hemorrhage. Maintenance therapy commonly uses rituximab or azathioprine to prevent relapse. Avacopan, a complement C5a receptor inhibitor, has been approved as an adjunctive treatment. Despite advances in therapy, MPA carries significant morbidity related to both the disease itself and treatment-related side effects, and relapses are common, necessitating long-term monitoring.

Also known as:

Clinical phenotype terms— hover any for plain English:

Crescentic glomerulonephritisHP:0008653Increased inflammatory responseHP:0012649OliguriaHP:0100520GlomerulopathyHP:0100820Subcutaneous hemorrhageHP:0001933PeritonitisHP:0002586
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

5 events
Nov 2025Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Bayer — PHASE3

TrialRECRUITING
Sep 2025An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera

Urmila DIwekar — PHASE1, PHASE2

TrialRECRUITING
Jul 2025Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)

Instituto Valenciano de Infertilidad, IVI VALENCIA — NA

TrialRECRUITING
Apr 2024Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

Fang Wang — NA

TrialRECRUITING
Dec 2023A Study of TCD601 in de Novo Renal Transplant Recipients

ITB-Med LLC — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Tavneos

avacopan· ChemoCentryx, Inc.
indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic

indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids

No actively recruiting trials found for Microscopic polyangiitis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Microscopic polyangiitis community →

Specialists

Showing 25 of 41View all specialists →
MP
Masayoshi Harigai, MD, PhD
Specialist
PI on 1 active trial
FP
Fadi Fakhouri, Pr
Specialist
PI on 1 active trial
PM
Peter A Merkel, MD, MPH
Tampa, Florida
Specialist

Rare Disease Specialist

PI on 7 active trials
JM
John H Stone, MD
Specialist
PI on 2 active trials
CM
Christian Pagnoux, MD
Specialist
PI on 1 active trial
LP
Lorraine Harper, PhD
BOSTON, MA
Specialist
PI on 1 active trial
DM
David Massicotte-Azarniouch, MD, MSc
CHAPEL HILL, NC
Specialist
PI on 1 active trial
KL
Kristen Lee
Specialist
PI on 1 active trial535 Microscopic polyangiitis publications
RM
Robert Micheletti, MD
PHILADELPHIA, PA
Specialist
PI on 2 active trials
FP
Fernando C. Fervenza, M.D., Ph.D.
ROCHESTER, MN
Specialist
PI on 5 active trials
TM
Trial Manager
Specialist
PI on 3 active trials2 Microscopic polyangiitis publications
JM
Jonathan London, MD
MILWAUKEE, WI
Specialist
PI on 1 active trial
MM
Manee Rattanachaiyanont, M.D.
Specialist
PI on 2 active trials
VM
Vera Halpern, MD
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Microscopic polyangiitis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Microscopic polyangiitisForum →

No community posts yet. Be the first to share your experience with Microscopic polyangiitis.

Start the conversation →

Latest news about Microscopic polyangiitis

Disease timeline:

New recruiting trial: Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

A new clinical trial is recruiting patients for Microscopic polyangiitis

New recruiting trial: An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera

A new clinical trial is recruiting patients for Microscopic polyangiitis

New recruiting trial: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

A new clinical trial is recruiting patients for Microscopic polyangiitis

New recruiting trial: Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)

A new clinical trial is recruiting patients for Microscopic polyangiitis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Microscopic polyangiitis

What is Microscopic polyangiitis?

Microscopic polyangiitis (MPA) is a rare systemic autoimmune disease classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It is characterized by necrotizing inflammation of small blood vessels (capillaries, venules, and arterioles) without granulomatous formation, distinguishing it from granulomatosis with polyangiitis (formerly Wegener's). MPA primarily affects the kidneys and lungs, though it can involve virtually any organ system including the skin, peripheral nerves, gastrointestinal tract, and musculoskeletal system. Most patients are positive for perinuclea

How is Microscopic polyangiitis inherited?

Microscopic polyangiitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Microscopic polyangiitis typically begin?

Typical onset of Microscopic polyangiitis is adult. Age of onset can vary across affected individuals.

Which specialists treat Microscopic polyangiitis?

25 specialists and care centers treating Microscopic polyangiitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.